Tumor necrosis factor-alfa and monocyte chemoattractant protein-1 gene polymorphisms in kidney transplant recipients

الملخص EN

Tumor necrosis factor-alfa (TNF-α) gene polymorphism is supposed to have a significant influence on the incidence of acute rejection in renal transplantation.

The monocyte chemoattractant protein-1 (MCP-1) is another factor supposed to modulate graft rejection.

We studied TNF-α and MCP-1 gene polymorphisms in 84 kidney allograft recipients with polymerase chain reaction and restriction fragment length polymorphism and their serum levels by enzyme-linked immunosorbent assay.

The patients were classified into two groups based on their outcomes : Group I (n = 47) recipients with stable graft function as the control group and group II (n = 37) recipients who experienced acute graft rejection episodes in the first 30 days post-transplantation.

A significantly higher incidence of TNF 2 / TNF 2 genotype was observed among patients with acute graft rejection in comparison with the control group (40.5 % and 19.2 % respectively, P < 0.05), while no statistically significant differences were observed in the TNF 1 / TNF 1 genotype between the groups (59.4 % and 80.8 %, respectively, P > 0.05).

A significant elevation of serum TNF-α levels was found in group II than group I and between TNF 2 genotype compared with that of TNF1 genotype within group II recipients.

Distribution of MCP-1 genotypes in patients with and without acute rejection episodes was not significantly different (70.2 % and 76.6 % for MCP-1 A / A and 29.7 % and 23.4 % for MCP-1 G / G, respectively, P > 0.05).

The serum MCP-1 levels were not significantly different between the groups and between MCP-1 G / G genotype and MCP-1 A / A genotype in group II recipients.

In conclusion, TNF-α gene polymorphism or its serum levels may identify patients at risk of acute rejection, where patients with TNF 2 / TNF 2 genotype or high serum TNF-α levels are more likely to have acute rejection episodes, while there was no relation between MCP-1 genotype or its serum levels and acute rejection.